Latest Press Releases
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembrolizumab
– PRIMUS-006 study led by Professors David Chang and Jeff Evans of the University of Glasgow – – Phase II study is evaluating a novel combination in first-line metastatic pancreatic cancer – GLASGOW, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- The Precision-Panc...
Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
Uxbridge, United Kingdom – April 29, 2024 – Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema,...
Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101
Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement significant oncology drug development experience of Immodulon’s new management...
Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer
Richard Couch, formerly at Celgene, appointed as Chief Technology Officer Owen Vaughan, formerly at Taiho Oncology, appointed as Chief Regulatory Officer Appointments add decades of industry experience to support advancement of IMM-101 into a pivotal trial in...
Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer
Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal trial in...
Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer
Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the Board Gertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive Officer Peter Greaney, formerly at ADC Therapeutics and Celgene, appointed as Chief Business Officer...